90% of frontline AML patients achieved remission with mipletamig plus ven/aza, surpassing the 66% rate seen with ven/aza alone. No cytokine release syndrome (CRS) has been reported in the RAINIER ...

Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...

Fifteen healthcare organizations, including Loma Linda University Medical Center, have been selected to participate in a national study intended to enhance patient safety and quality of care in health ...

The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience. BY Jacob Kupietzky While ...

Atebimetinib is an investigational oral deep cyclic inhibitor that targets MEK in the MAPK pathway, which is activated in many solid tumors including pancreatic cancer. Its mechanism of action is ...

As organizations seek to evolve their patient support programs, five key actions can help bridge the data gap between analytics teams and patient care teams: Data will always be essential in measuring ...

NEW YORK, March 11, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that ...

NEW ORLEANS ― An interdisciplinary pilot program effectively deals with behavioral disturbances arising from delirium, dementia, or other mental illnesses in hospitalized older adults ― while keeping ...

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy "These data from the ...

CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy By CREATE Medicines, Inc.